Effect of routine vs on-demand nebulization of acetylcysteine with salbutamol on accumulation of airway secretions in endotracheal tubes: substudy of a randomized clinical trial

Intensive Care Medicine Experimental

Table 3 Association between CSA and patient variables

Variable	Univariate	P value	Multivariate	P value
Variable	estimate with 95% CI	P value	estimate with 95% CI	P value
Randomization group	− 1.1 (− 5.1 to 3.0)	0.60	1.3 (− 4.6 to 7.3)	0.65
Duration of mechanical ventilation	− 0.2 (− 0.5 to 0.1)	0.21	− 0.1 (− 0.6 to 0.3)	0.56
Reason for mechanical ventilation (direct pulmonary vs. indirect pulmonary)	1.6 (− 3.6 to 6.9)	0.54	5.1 (− 3.5 to 13.7)	0.24
Gender	2.8 (− 1.5 to 7.1)	0.19	3.1 (− 4.0 to 10.3)	0.39
APACHE II	− 0.2 (− 0.5 to 0.2)	0.43	− 0.2 (− 0.7 to 0.2)	0.35
Tube diameter	− 1.2 (− 5.4 to 3.0)	0.58	0.5 (− 6.9 to 7.9)	0.89
Age	− 0.0 (− 0.2 to 0.1)	0.71
History of diabetes	0.5 (− 4.7 to 5.8)	0.84
History of CVD	− 2.0 (− 6.9 to 3.0)	0.42
History of pulmonary disease	1.6 (− 5.7 to 8.9)	0.66
BMI	− 0.0 (− 0.4 to 0.3)	0.98
Total amount of acetylcysteine nebulizations	− 0.0 (− 0.1 to 0.1)	0.77
Total amount of salbutamol nebulizations	− 0.0 (− 0.1 to 0.1)	0.91
Acetylcysteine nebulizations per day	− 0.1 (− 0.5 to 0.3)	0.64
Salbutamol nebulizations per day	− 0.0 (− 0.4 to 0.3)	0.81
Total amount of nebulizations per day	− 0.1 (− 0.5 to 0.3)	0.69
Amount of acetylcysteine nebulization days	− 0.0 (− 0.3 to 0.3)	0.89
Amount of salbutamol nebulization days	0.0 (− 0.3 to 0.3)	0.95
Nebulizations days	− 0.0 (− 0.3 to 0.3)	0.97
Total amount of nebulizations	− 0.0 (− 0.1 to 0.1)	0.79

CI, confidence interval; APACHE II, Acute Physiology and Chronic Health Evaluation II; CVD, cardio-vascular disease; BMI, body mass index